LEARNING OBJECTIVES

• Identify clinical features, including differential diagnoses for the various hematologic malignancies
• Identify late effects and survivorship issues following cellular therapy
• Implement strategies that incorporate state-of-the-art genomic analyses for hematologic malignancies
• Identify new data for Hereditary Myeloid Disorders
• Select appropriate hematologic malignancy patients for immunotherapy
• Select appropriate clinical trials for hematologic malignancies
• Identify the major patient management issues experienced by the Interprofessional care team associated with hematologic malignancies
• Apply new strategies for incorporating therapies that target metabolism in blood cancers

ACCREDITATION

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME).Penn Medicine designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.